000289128 001__ 289128
000289128 005__ 20241218120831.0
000289128 0247_ $$2doi$$a10.1111/cas.16135
000289128 0247_ $$2pmid$$apmid:38523358
000289128 0247_ $$2ISSN$$a1344-6428
000289128 0247_ $$2ISSN$$a0910-5050
000289128 0247_ $$2ISSN$$a1347-9032
000289128 0247_ $$2ISSN$$a1349-7006
000289128 0247_ $$2ISSN$$a1876-4673
000289128 037__ $$aDKFZ-2024-00595
000289128 041__ $$aEnglish
000289128 082__ $$a610
000289128 1001_ $$0P:(DE-He78)43ea0369702f56d45fa4a32df9f49aca$$aRaut, Janhavi$$b0$$eFirst author$$udkfz
000289128 245__ $$aCancer-specific risk prediction with a serum microRNA signature.
000289128 260__ $$aTokyo$$bAssoc.$$c2024
000289128 3367_ $$2DRIVER$$aarticle
000289128 3367_ $$2DataCite$$aOutput Types/Journal article
000289128 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1717421989_4831
000289128 3367_ $$2BibTeX$$aARTICLE
000289128 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000289128 3367_ $$00$$2EndNote$$aJournal Article
000289128 500__ $$a#EA:C070#LA:C070#LA:C120# / 2024 Jun;115(6):2049-2058
000289128 520__ $$aWe recently derived and validated a serum-based microRNA risk score (miR-score) that predicted colorectal cancer (CRC) occurrence with very high accuracy within 14 years of follow-up in a population-based cohort study from Germany (ESTHER cohort). Here, we aimed to evaluate associations of the CRC-specific miR-score with the risk of developing other common cancers, including female breast cancer (BC), lung cancer (LC), and prostate cancer (PC), in the ESTHER cohort. MicroRNAs (miRNAs) were profiled by quantitative real-time PCR in serum samples collected at baseline from randomly selected incident cases of BC (n = 90), LC (n = 88), and PC (n = 93) and participants without diagnosis of CRC, LC, BC, or PC (controls, n = 181) until the end of the 17-year follow-up. Multivariate logistic regression models were used to evaluate the associations of the miR-score with BC, LC, and PC incidence. The miR-score showed strong inverse associations with BC and LC incidence [odds ratio per 1 standard deviation increase: 0.60 (95% confidence interval [CI] 0.43-0.82), p = 0.0017, and 0.64 (95% CI 0.48-0.84),p = 0.0015, respectively]. Associations with PC were not statistically significant but pointed in the positive direction. Our study highlights the potential of serum-based miRNA biomarkers for cancer-specific risk prediction. Further large cohort studies aiming to investigate, validate, and optimize the use of circulating miRNA signatures for cancer risk assessment are warranted.
000289128 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000289128 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000289128 650_7 $$2Other$$abreast cancer
000289128 650_7 $$2Other$$acirculating miRNA
000289128 650_7 $$2Other$$acolorectal cancer
000289128 650_7 $$2Other$$alung cancer
000289128 650_7 $$2Other$$aprostate cancer
000289128 650_7 $$2Other$$arisk prediction
000289128 650_7 $$2Other$$arisk stratification
000289128 7001_ $$0P:(DE-He78)ac7aed57f26354e8a484b5d257f7bada$$aBhardwaj, Megha$$b1$$udkfz
000289128 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b2$$udkfz
000289128 7001_ $$aHolleczek, Bernd$$b3
000289128 7001_ $$0P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aSchrotz-King, Petra$$b4$$udkfz
000289128 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b5$$eLast author$$udkfz
000289128 773__ $$0PERI:(DE-600)2115647-5$$a10.1111/cas.16135$$gp. cas.16135$$n6$$p2049-2058$$tCancer science$$v115$$x1344-6428$$y2024
000289128 8767_ $$8W-2024-00027-b$$92024-05-28$$d2024-12-18$$eAPC$$jZahlung erfolgt
000289128 909CO $$ooai:inrepo02.dkfz.de:289128$$pVDB$$pOpenAPC$$popenCost
000289128 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)43ea0369702f56d45fa4a32df9f49aca$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000289128 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ac7aed57f26354e8a484b5d257f7bada$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000289128 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000289128 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000289128 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000289128 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000289128 9141_ $$y2024
000289128 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000289128 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000289128 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-25
000289128 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER SCI : 2022$$d2023-10-25
000289128 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000289128 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-25
000289128 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-25
000289128 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000289128 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-25
000289128 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-25
000289128 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-25
000289128 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-10-23T21:03:42Z
000289128 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-10-23T21:03:42Z
000289128 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2022-10-23T21:03:42Z
000289128 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCER SCI : 2022$$d2023-10-25
000289128 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-25
000289128 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-25
000289128 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000289128 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000289128 915pc $$0PC:(DE-HGF)0002$$2APC$$aDFG OA Publikationskosten
000289128 915pc $$0PC:(DE-HGF)0003$$2APC$$aDOAJ Journal
000289128 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000289128 9202_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000289128 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000289128 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000289128 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000289128 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000289128 980__ $$ajournal
000289128 980__ $$aVDB
000289128 980__ $$aI:(DE-He78)C070-20160331
000289128 980__ $$aI:(DE-He78)C120-20160331
000289128 980__ $$aI:(DE-He78)HD01-20160331
000289128 980__ $$aUNRESTRICTED
000289128 980__ $$aAPC